Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence-specific RNA capture

Oncology Reports

Volumn 34, Issue 5, 2015, Pages 2439-2444

  Zheng, Kewen ^a   Dou, Yaling ^a   He, Linfu ^b   Li, Hanzhong ^a   Zhang, Zhicai ^b   Chen, Yu ^a   Ye, Ali ^a   Liu, Wenjing ^a   Kong, Lingjun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Diagnosis; Magnetic beads; Prostate cancer; Prostate cancer antigen 3

Indexed keywords

MESSENGER RNA; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MIDDLE AGED; PCA3 GENE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PSA GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA PURIFICATION; RNA SEQUENCE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; URINALYSIS; VERY ELDERLY; DIFFERENTIAL DIAGNOSIS; EARLY CANCER DIAGNOSIS; FEMALE; NUCLEOTIDE SEQUENCE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; RNA STABILITY; TOTAL QUALITY MANAGEMENT; TUMOR CELL LINE; URINE;

AGED; ANTIGENS, NEOPLASM; BASE SEQUENCE; CELL LINE, TUMOR; DIAGNOSIS, DIFFERENTIAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; QUALITY IMPROVEMENT; RNA STABILITY; ROC CURVE;

EID: 84941957304     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4266     Document Type: Article

References (32)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241, 2012.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Surveillance E; End Results (SEER) Program: (www.seer.cancer. gov) SEER.∗Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2010) , National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013. Underlying mortality data provided by NCHS (www.cdc. gov/nchs).
4. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L and He J: The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 32: 106-112, 2013.
5. Smith RA, Cokkinides V and Eyre HJ: Cancer screening in the United States, 2007: A review of current guidelines, practices, and prospects. CA Cancer J Clin 57: 90-104, 2007.
6. Slawin KM, Ohori M, Dillioglugil O and Scardino PT: Screening for prostate cancer: An analysis of the early experience. CA Cancer J Clin 45: 134-147, 1995.
7. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
8. Cher ML and Carroll PR: Screening for prostate cancer. West J Med 162: 235-242, 1995.
9. Schmidt JD: Clinical diagnosis of prostate cancer. Cancer 70 (Suppl 1): 221-224, 1992.
10. Lilja H: Biology of prostate-specific antigen. Urology 62 (Suppl 1): 27-33, 2003.
11. Yates DR and Catto JW: Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: How molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours. World J Urol 31: 21-29, 2013.
12. Clarke RA, Zhao Z, Guo AY, Roper K, Teng L, Fang ZM, Samaratunga H, Lavin MF and Gardiner RA: New genomic structure for prostate cancer specific gene PCA3 within BMCC1: Implications for prostate cancer detection and progression. PLoS One 4: e4995, 2009.
13. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P and Allen NE; NHS Prostate Cancer Risk Management: Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis. Eur Urol 48: 386-399, 2005.
14. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N and Isaacs WB: DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59: 5975-5979, 1999.
15. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA and Schalken JA: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8-16, 2003.
16. Schalken JA, Hessels D and Verhaegh G: New targets for therapy in prostate cancer: Differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 62 (Suppl 1): 34-43, 2003.
17. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW and Schalken JA: DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62: 2695-2698, 2002.
18. Day JR, Jost M, Reynolds MA, Groskopf J and Rittenhouse H: PCA3: From basic molecular science to the clinical lab. Cancer Lett 301: 1-6, 2011.
19. Ploussard G and de la Taille A: Urine biomarkers in prostate cancer. Nat Rev Urol 7: 101-109, 2010.
20. Roobol MJ: Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol 21: 225-229, 2011.
21. Roobol MJ, Haese A and Bjartell A: Tumour markers in prostate cancer III: Biomarkers in urine. Acta Oncol 50 (Suppl 1): 85-89, 2011.
22. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, et al: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69: 532-535, 2007.
23. Janegitz BC, Cancino J and Zucolotto V: Disposable biosensors for clinical diagnosis. J Nanosci Nanotechnol 14: 378-389, 2014.
24. McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M and Phillips PA: Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol 5: 2, 2014.
25. Thakor AS and Gambhir SS: Nanooncology: The future of cancer diagnosis and therapy. CA Cancer J Clin 63: 395-418, 2013.
26. Chan CP, Cheung YC, Renneberg R and Seydack M: New trends in immunoassays. Adv Biochem Eng Biotechnol 109: 123-154, 2008.
27. Sandhu A, Handa H and Abe M: Synthesis and applications of magnetic nanoparticles for biorecognition and point of care medical diagnostics. Nanotechnology 21: 442001, 2010.
28. Casadio V, Calistri D, Salvi S, Gunelli R, Carretta E, Amadori D, Silvestrini R and Zoli W: Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: A pilot study. Biomed Res Int 2013: 270457, 2013.
29. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al: Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6: 224ra24, 2014.
30. Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich MG, et al: Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level ≤4.0 ng per milliliter. Eur Urol 53: 750-757, 2008.
31. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
32. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, et al: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52: 1089-1095, 2006.